Condition

Metastatic Breast Cancer clinical trials and research

• 140Clinical trials
• 45NIH research projects
• 2New in 30 days
• 52Countries

Newest Metastatic Breast Cancer clinical trials

All recruiting trials (140)

• PRT13722 in advanced HR+/HER2- breast cancer

  This early study tests PRT13722, by itself and with standard therapies, to see if it is safe and has any signs of activity in adults with HR+/HER2- breast cancer who have progressed on prior treatments.

  Recruiting Phase 1 Prelude Therapeutics Incorporated · Maumee, Ohio · NCT07905001

• Personalized treatment after endocrine therapy failure in metastatic breast cancer

  The study tests whether using a patient’s fresh tumor sample to try different drugs outside the body can help pick the next therapy for hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy.

  Recruiting Tel-Aviv Sourasky Medical Center · Tel Aviv · NCT07895160

• SSGJ-612 plus a HER2-targeted ADC in HR-positive, HER2-low metastatic breast cancer

  This phase II study tests whether adding SSGJ-612 to a HER2-targeted antibody-drug conjugate helps people with HR-positive, HER2-low or ultralow metastatic breast cancer.

  Recruiting Phase 2 Shenyang Sunshine Pharmaceutical Co., LTD. · Guangzhou, Guangdong · NCT07757230

• SMP-656 in HER2-positive advanced breast cancer after ADC therapy

  This trial tests whether SMP-656 given by IV every 3 weeks can help people with HER2-positive locally advanced or metastatic breast cancer who progressed after a HER2-targeted antibody-drug conjugate.

  Recruiting Phase 2 Chengdu SciMount Pharmatech Co., Ltd. · Hefei, Anhui and 14 other locations · NCT07726342

• Entinostat with Pyrotinib and Endocrine Therapy in HER2-positive, HR-positive Advanced Breast Cancer after Trastuzumab Failure

  This study tests whether adding entinostat to pyrotinib and hormone therapy is safe and helps patients with advanced HR+/HER2+ breast cancer who progressed after trastuzumab.

  Recruiting Phase 1/2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07708194

• T-DXd–based therapy followed by targeted HER2 blockade and endocrine therapy in first-line HER2+ / HR+ metastatic breast cancer

  This trial tests a sequence of therapies starting with T-DXd plus pertuzumab, then a maintenance phase with dual HER2 blockade, endocrine therapy, and CDK4/6 inhibitor, with a retreatment option of T-DXd if disease progresses.

  Recruiting at 5 sites Phase 3 Daiichi Sankyo · Columbia, Maryland and 4 other locations · NCT07683754

• Fasting with Capivasertib in Metastatic Breast Cancer

  This study tests whether a prolonged fasting protocol can be safely used alongside capivasertib in people with metastatic breast cancer to see if it helps treatment work.

  Recruiting University of Minnesota · Minneapolis, Minnesota · NCT07624617

• First-in-human imaging test of the GRPR-targeted theranostic pair for advanced breast or prostate cancer

  This early feasibility study tests a GRPR-targeted imaging agent for PET and a low-dose radiopharmaceutical for SPECT in adults with advanced breast or prostate cancer to see if it is safe and can image tumors.

  Recruiting Early Phase 1 Integrated Haematology and Oncology Network · Perth, Western Australia · NCT07608848

• Autologous p95HER2 CAR-T Cells in HER2-Positive Cancers

  This study tests whether a patient’s own CAR-T cells targeting p95HER2 can be safely given to adults with HER2-positive metastatic cancers to see if it can help control tumors.

  Recruiting Phase 1 Vall d'Hebron Institute of Oncology · Barcelona, Catalonia and 1 other locations · NCT07593820

• HER2+ Metastatic Breast Cancer in Kazakhstan (observational)

  This study tests how patients with HER2-positive metastatic breast cancer who are receiving anti-HER2 therapy fare across several Kazakh centers.

  Recruiting at 10 sites AstraZeneca · Oral, Kazakhstan and 11 other locations · NCT07593196

• UGT1A1 gene and side effects from certain antibody-drug treatments for advanced breast cancer

  This project will test whether common UGT1A1 gene variants explain who gets worse side effects from antibody-drug conjugates (sacituzumab-govitecan, trastuzumab-deruxtecan, or datopotamab-deruxtecan) in adults with advanced breast cancer.

  Recruiting Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental · Granada, Granada · NCT07582887

• HLD-0117 treatment for ER-positive metastatic breast cancer

  This will test whether the oral drug HLD-0117 is safe and can shrink tumors in people with ER-positive metastatic or locally advanced breast cancer who have progressed after prior treatments.

  Recruiting at 7 sites Phase 1 Janssen Research & Development, LLC · New Haven, Connecticut and 6 other locations · NCT07524855

• Generative AI Education Tool for Breast Cancer Care

  Researchers are testing an AI-powered teaching tool to help adults with breast cancer understand their care while receiving treatment from UCSF physicians.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07512271

• Pulsed Electric Field Ablation for Metastatic Breast Cancer

  This trial tests a one-time pulsed electric field ablation to treat superficial metastatic breast cancer lesions in adults, guided by imaging.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07487844

• Inavolisib-based treatment for endocrine-resistant PIK3CA-mutated HR+/HER2- advanced breast cancer

  This trial tests an inavolisib-based regimen in people in China who have endocrine-resistant, PIK3CA-mutated, hormone receptor–positive, HER2‑negative locally advanced or metastatic breast cancer after finishing adjuvant endocrine therapy.

  Recruiting at 32 sites Hoffmann-La Roche · Xiamen, Fujian and 31 other locations · NCT07347600

• Adaptive biomarker-driven therapies for metastatic breast cancer

  This trial tests whether matching targeted drug combinations to tumor biomarkers helps people with ER+/HER2- or triple-negative metastatic breast cancer who are starting second-line treatment.

  Recruiting at 4 sites Phase 2 UNC Lineberger Comprehensive Cancer Center · New Haven, Connecticut and 5 other locations · NCT07340541

• Increasing exercise for people with metastatic breast cancer using the Get Real and Heel program

  This project will try offering the Get Real and Heel (GRH) exercise program to people with metastatic breast cancer at UNC to see if it increases physical activity and improves symptoms and quality of life.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07313306

• Blood test for PTEN and organ-specific microRNAs to detect metastatic patterns in breast cancer

  We will test whether blood levels of PTEN and organ-specific microRNAs can distinguish women with metastatic breast cancer from those with early-stage disease and healthy controls.

  Recruiting Atlas University · Istanbul, Istanbul · NCT07297134

• Capivasertib plus endocrine therapy for HR+/HER2- advanced breast cancer after progression on endocrine treatment

  This trial will test whether adding capivasertib to standard endocrine therapy helps adults with HR+/HER2- advanced or metastatic breast cancer who progressed on prior endocrine treatment stay on treatment longer and maintain quality of life.

  Recruiting at 15 sites Phase 3 Women's Cancer Study Group GmbH · Anderlecht and 15 other locations · NCT07281833

• Morning versus evening timing of hormone therapy for metastatic breast and prostate cancer

  This pilot will test whether taking hormone-based cancer drugs in the morning or in the evening works better for people with metastatic breast or prostate cancer.

  Recruiting at 2 sites Phase 4 Ottawa Hospital Research Institute · Kitchener, Ontario and 2 other locations · NCT07252726

• Atlas of cell organelles and protein patterns in breast cancer subtypes

  This project will collect tumor and blood samples from people with early or newly metastatic breast cancer to test how much fat accumulates in tiny cell structures (lipid droplets) and to map protein patterns across tumor subtypes.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07233928

• TheraBionic P1 device in advanced HR-positive, HER2-negative breast cancer

  This trial tests whether the TheraBionic P1 device can help women with advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed on standard therapies, by looking at survival and disease control.

  Recruiting at 8 sites Barbara Ann Karmanos Cancer Institute · Bay City, Michigan and 7 other locations · NCT07227831

• Capecitabine with or without elacestrant for ER-positive advanced breast cancer

  This trial will try adding elacestrant to capecitabine to see if it helps people with ER-positive, HER2-negative advanced breast cancer that stopped responding to CDK4/6 inhibitors.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07222215

• 12-week home exercise program to boost energy and reduce fatigue for people on Enhertu

  This 12-week home-based aerobic and resistance exercise program will try to reduce cancer-related fatigue in people with metastatic breast cancer who are receiving Enhertu.

  Recruiting Phase 2 University of Utah · Salt Lake City, Utah · NCT07203378

• Elacestrant plus trastuzumab deruxtecan for HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after CDK4/6 and endocrine therapy

  This trial tests whether combining elacestrant with trastuzumab deruxtecan helps people with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer that progressed after CDK4/6 inhibitor and endocrine treatment.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07198724

• Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer

  A lifestyle program is tried to see if women with stable HR+/HER2- metastatic breast cancer can take part and stay in an 8-week online or mixed-format intervention.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT07179809

• Palazestrant plus ribociclib as first-line treatment for ER+/HER2- advanced breast cancer

  This trial will test whether using palazestrant instead of letrozole, both given with ribociclib, helps adults with ER+/HER2- advanced breast cancer who have not had prior systemic treatment for their advanced disease.

  Recruiting at 198 sites Phase 3 Olema Pharmaceuticals, Inc. · Hot Springs, Arkansas and 199 other locations · NCT07085767

• Serial multisite image-guided biopsies to track breast cancer evolution

  The team will try taking repeated image-guided biopsies and blood samples from adults with metastatic or advanced breast cancer to see how their tumors change during treatment.

  Recruiting Royal Marsden NHS Foundation Trust · London · NCT07084571

• First human use of [177Lu]Lu-ABY-271 to target HER2-positive metastatic breast cancer

  This first-in-human Phase 1 test will see if the radiopharmaceutical [177Lu]Lu-ABY-271 is safe and how it distributes in the body for people with HER2-positive metastatic breast cancer.

  Recruiting at 3 sites Phase 1 Affibody · Gothenburg and 2 other locations · NCT07081555

• Treatment options after targeted therapy stops working in advanced breast cancer

  This study will see how well different treatments work for people with advanced breast cancer who have stopped responding to CDK4/6 inhibitors, PIK3CA inhibitors, or T-DXd.

  Recruiting Hunan Cancer Hospital · Changsha, Hunan · NCT07073755

• SKB264 versus investigator's choice chemotherapy for unresectable or metastatic HR+/HER2- breast cancer

  This will test whether SKB264 works better than commonly chosen chemotherapy for adults with unresectable or metastatic HR+/HER2- breast cancer who no longer benefit from hormone therapy.

  Recruiting at 2 sites Phase 3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07071337

• Why some new treatments work or stop working in advanced breast cancer

  This project will see if biological markers explain why people with advanced breast cancer respond or become resistant to newer treatments like ADCs, immunotherapy, CDK inhibitors, and PARP inhibitors.

  Recruiting at 5 sites Hellenic Cooperative Oncology Group · Athens and 4 other locations · NCT07066917

• Surgery and focused radiation plus HER2-targeted therapy for oligometastatic HER2-positive breast cancer

  This will test whether adding surgery and precise radiation to standard HER2-targeted treatment helps people with oligometastatic HER2-positive breast cancer whose disease is controlled after initial therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07053085

• Toxicity markers for Trastuzumab‑Deruxtecan in advanced breast cancer

  This project will test whether blood markers can predict serious side effects, including interstitial lung disease, in adults with metastatic HER2‑positive or HER2‑low breast cancer who are treated with Trastuzumab‑Deruxtecan.

  Recruiting European Institute of Oncology · Milan · NCT07049133

• HRS-8080 versus doctor‑chosen treatments for locally advanced or metastatic breast cancer

  This trial will test whether the oral drug HRS-8080 works better than treatments chosen by doctors for women with locally advanced or metastatic breast cancer whose disease progressed after prior endocrine therapy.

  Recruiting at 2 sites Phase 3 Shandong Suncadia Medicine Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07024173

• TQB2102 injection versus trastuzumab emtansine for HER2-positive advanced breast cancer

  This trial tests whether TQB2102 injection works as well as trastuzumab emtansine for adults with HER2-positive unresectable or metastatic breast cancer.

  Recruiting at 2 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bengbu, Anhui and 30 other locations · NCT07008976

• Combining FWD1802 with CDK4/6 inhibitors or everolimus for ER+/HER2- advanced breast cancer

  This trial tests whether adding FWD1802 to CDK4/6 inhibitors or everolimus helps people with ER-positive/HER2-negative unresectable locally advanced or metastatic breast cancer who have progressed on or cannot use standard therapy.

  Recruiting Phase 1/2 Forward Pharmaceuticals Co., Ltd. · Shanghai · NCT07002177

• Emotional distress and first-line treatment outcomes in metastatic breast cancer

  This study will see if emotional distress at the start of treatment changes how well first-line therapies work for people with metastatic breast cancer.

  Recruiting at 8 sites European Institute of Oncology · Ancona and 36 other locations · NCT06994377

• Assessing Genomic Profiling's Impact on Metastatic Breast Cancer Treatment in Spain

  This study is trying to see if using genetic information from patients with metastatic breast cancer in Spain can help doctors create better, personalized treatment plans for them.

  Recruiting SOLTI Breast Cancer Research Group · Barcelona, Barcelona · NCT06991946

• RLY-2608 plus fulvestrant versus capivasertib plus fulvestrant for PIK3CA‑mutant HR+/HER2‑ advanced breast cancer

  This trial tests whether RLY-2608 combined with fulvestrant works better than capivasertib combined with fulvestrant for adults with HR+/HER2‑ advanced breast cancer that has a PIK3CA mutation and progressed after a CDK4/6 inhibitor.

  Recruiting at 254 sites Phase 3 Relay Therapeutics, Inc. · Gilbert, Arizona and 253 other locations · NCT06982521

• CXCR4-targeted [68Ga]Ga-PentixaFor PET/CT imaging for metastatic triple-negative breast cancer

  This study will test whether a CXCR4-targeted PET/CT scan ([68Ga]Ga-PentixaFor) can better detect metastatic triple-negative breast cancer than the standard [18F]FDG PET/CT in adults.

  Recruiting Institut Cancerologie de l'Ouest · Saint-Herblain · NCT06962163

• Comparing methods to capture circulating tumor cells in metastatic breast or prostate cancer

  This one-day test will compare three blood-based methods (CellSearch®, Parsortix®, and SmartCatch®) to see which best finds circulating tumor cells in people with metastatic breast or prostate cancer before they start a new line of treatment.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06904625

• Combining bortezomib and cisplatin for advanced breast cancer

  This study is testing if combining two cancer drugs, bortezomib and cisplatin, can help women with advanced breast cancer who haven't had success with other treatments.

  Recruiting Phase 1 Sun Yat-sen University · Guangzhou, Guangdong · NCT06900647

• Comparing FDG-PET/CT and CT for Monitoring Metastatic Breast Cancer

  This study is testing if a special type of imaging called FDG-PET/CT can find problems in metastatic breast cancer patients sooner than regular CT scans, so they can start new treatments faster.

  Recruiting at 9 sites Odense University Hospital · Aalborg and 10 other locations · NCT06877949

• Promoting resilience in Black women with metastatic breast cancer

  This study is testing a new program to see if it can help Black women with metastatic breast cancer feel stronger and improve their quality of life.

  Recruiting at 2 sites UNC Lineberger Comprehensive Cancer Center · Birmingham, Alabama and 1 other locations · NCT06855654

• Finding the best dose of BNT323 and BNT327 for advanced breast cancer

  This study is testing the best dose of a new combination treatment for advanced breast cancer to see how well it works and if it's safe for patients.

  Recruiting at 84 sites Phase 1/2 BioNTech SE · Beverly Hills, California and 83 other locations · NCT06827236

• Targeted palliative care program for people with metastatic breast cancer

  This trial will test a five-session TARGET-PC palliative care program to see if it helps people with metastatic breast cancer and their caregivers communicate better with clinicians and manage symptoms.

  Recruiting at 3 sites Massachusetts General Hospital · Boston, Massachusetts and 2 other locations · NCT06795529

• Treatment for PD-L1-positive metastatic triple-negative breast cancer

  This study is testing a new treatment plan that combines two drugs after initial therapy to see if it helps people with PD-L1-positive metastatic triple-negative breast cancer live longer without their cancer getting worse.

  Recruiting Phase 2 Japan Breast Cancer Research Group · Koto-ku, 3-8-31, Tokyo · NCT06793553

• Testing OP-3136 for advanced solid tumors

  This study is testing a new drug called OP-3136 to see if it can safely help people with advanced solid tumors.

  Recruiting at 24 sites Phase 1 Olema Pharmaceuticals, Inc. · Gilbert, Arizona and 24 other locations · NCT06784193

• Antibody-drug conjugates for first- and second-line treatment of metastatic HER2‑negative and triple‑negative breast cancer

  This prospective registry will collect real-world data to see how FDA-approved antibody-drug conjugates work as first- or second-line treatments for adults with metastatic HER2‑negative or triple-negative breast cancer.

  Recruiting at 3 sites University of California, San Francisco · San Francisco, California and 2 other locations · NCT06774027

• Testing a new combination of drugs for advanced breast cancer

  This study is testing a new combination of drugs to see if they can help adults with advanced breast cancer that hasn't responded to previous treatments.

  Recruiting at 13 sites Phase 1 BeOne Medicines · Iowa City, Iowa and 13 other locations · NCT06756932

• Testing Abemaciclib with Radiation Therapy for Metastatic Breast Cancer

  This study is testing different doses of the drug abemaciclib in people with metastatic breast cancer who are also getting hormone therapy and radiation to see if it helps them better manage their symptoms.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06678269

• Testing new antibody drugs in advanced breast cancer patients who have used similar treatments before

  This study is testing new antibody drugs to see if they can help advanced breast cancer patients who have already tried similar treatments.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06649331

• Evaluating Inetetamab combinations for treating HER2 positive metastatic breast cancer

  This study is testing if a new drug called Inetetamab, used with either Pertuzumab or Pyrotinib, can improve treatment for people with HER2 positive metastatic breast cancer.

  Recruiting Phase 4 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Shanwei, Guangdong · NCT06641544

• Evaluating BBO-10203 for advanced solid tumors

  This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.

  Recruiting at 43 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Duarte, California and 43 other locations · NCT06625775

• Combining utidelone and capecitabine for treating brain metastases in triple-negative breast cancer

  This study is testing a new combination of two medications, utidelone and capecitabine, to see if they can help people with brain metastases from triple-negative breast cancer.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT06598046

• Treatment for advanced breast cancer using RYZ101

  This study is testing a new treatment called RYZ101 for people with advanced breast cancer that can't be removed by surgery to see if it helps manage their condition.

  Recruiting Phase 1/2 RayzeBio, Inc. · Phoenix, Arizona and 30 other locations · NCT06590857

• Evaluating trastuzumab deruxtecan in metastatic breast cancer with varying HER2 levels

  This study is testing how different levels of HER2 in metastatic breast cancer affect how well the drug trastuzumab deruxtecan works for patients.

  Recruiting at 26 sites Sun Yat-sen University · New Haven, Connecticut and 25 other locations · NCT06551220

• Treatment for HER2-negative metastatic breast cancer using two investigational drugs

  This study is testing if using two new drugs one after the other can help people with HER2-negative metastatic breast cancer live longer and feel better.

  Recruiting at 10 sites Phase 2 Dana-Farber Cancer Institute · Birmingham, Alabama and 10 other locations · NCT06533826

• Testing ERX-315 in patients with advanced solid tumors

  This study is testing a new treatment called ERX-315 to see if it is safe and effective for people with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 5 sites Phase 1 EtiraRx Australia Pty Ltd · Ryde, New South Wales and 4 other locations · NCT06533332

• Adaptive capecitabine therapy for metastatic ER-positive, HER2-negative breast cancer

  This trial will try using capecitabine with dose changes based on tumor imaging and blood markers in adults with metastatic ER-positive, HER2-negative breast cancer.

  Recruiting Phase 2 Mayo Clinic · Scottsdale, Arizona · NCT06525766

• Understanding the in-home hospice experience for breast cancer patients

  This study looks at how to improve hospice care for breast cancer patients at home by checking in with them and their caregivers through telehealth to see what works best.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06507930

• Personalized therapy using patient-derived organoids for metastatic breast cancer

  This study is testing whether using mini versions of a patient's breast tumor can help find the best treatment options for people with metastatic breast cancer.

  Recruiting at 2 sites Institut Curie · Paris and 2 other locations · NCT06459791

• Reducing treatment for metastatic HER2-positive breast cancer with undetectable cancer levels in blood tests.

  This study is testing if patients with HER2-positive metastatic breast cancer can safely stop their treatment after two years of good results and negative blood tests showing no cancer.

  Recruiting Phase 2 Unicancer · Rennes · NCT06450314

• Observing mutations in metastatic ER-positive breast cancer patients

  This study looks at how certain genetic changes in metastatic ER-positive breast cancer patients happen over time, by comparing blood tests and tissue samples from those who have and haven’t had treatment.

  Recruiting AstraZeneca · Salvador, Estado de Bahia and 5 other locations · NCT06417801

• Vaccine therapy for metastatic solid tumors

  This study is testing a new vaccine therapy to see if it can safely help people with certain types of advanced breast and stomach cancers fight their tumors better.

  Recruiting Phase 1 Indiana University · Indianpolis, Indiana · NCT06414733

• New treatment approach for metastatic breast cancer using existing drugs

  This study is testing a new way to use existing cancer drugs in a specific order to see if it can help women with hormone-positive, HER2-negative metastatic breast cancer who have already tried other treatments.

  Recruiting Phase 2 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT06409390

• Improving support for Black and Latina women with metastatic breast cancer

  This study is testing a new support program for Black and Latina women with metastatic breast cancer to see if it helps them feel better and access more resources compared to standard care.

  Recruiting Icahn School of Medicine at Mount Sinai · New York, New York · NCT06405828

• Measuring a biomarker for breast cancer treatment effectiveness

  This study is testing if measuring a specific biomarker can help doctors understand how well hormone treatments are working for people with advanced breast cancer.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT06388122

• Evaluating ESG401 for advanced breast cancer

  This study is testing a new treatment called ESG401 to see if it can help people with advanced breast cancer who haven't had success with other chemotherapy options.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06383767

• Alternative dosing strategy for CDK4/6 inhibitors in older patients with metastatic breast cancer

  This study is testing a new way to give CDK4/6 inhibitors to older patients with metastatic breast cancer to see if starting with a lower dose helps them stay on treatment longer and feel better.

  Recruiting at 92 sites Phase 3 American Society of Clinical Oncology · Chandler, Arizona and 91 other locations · NCT06377852

• Using 68Ga-ABS011 for imaging HER2 in metastatic breast cancer

  This study is testing a new imaging method using 68Ga-ABS011 to see if it can more accurately determine HER2 status in patients with metastatic breast cancer compared to standard tests.

  Recruiting at 6 sites Phase 2 Abscint NV/SA · Innsbruck, Tyrol and 6 other locations · NCT06369831

• Combining Alisertib with Endocrine Therapy for Advanced Breast Cancer

  This study is testing if adding a targeted therapy called alisertib to hormone treatment can help people with advanced breast cancer who haven’t responded to previous hormone therapies.

  Recruiting at 52 sites Phase 2 Puma Biotechnology, Inc. · Birmingham, Alabama and 52 other locations · NCT06369285

• New immunotherapy options for advanced triple negative breast cancer

  This study is testing a new combination of immunotherapy treatments for people with advanced triple-negative breast cancer to see if it can help them respond better to treatment.

  Recruiting Phase 2 The Netherlands Cancer Institute · Amsterdam, North Holland · NCT06342037

• Finding the right dose of zongertinib for HER2+ cancer treatment

  This study is testing the best dose of zongertinib to see if it can help adults with hard-to-treat HER2+ cancers shrink their tumors.

  Recruiting at 98 sites Phase 1/2 Boehringer Ingelheim · Cerritos, California and 103 other locations · NCT06324357

• Evaluating the effectiveness of sacituzumab govitecan in specific breast cancer patients

  This study is testing if a drug called sacituzumab govitecan can help people with advanced hormone receptor-positive breast cancer who have already been treated with another medication.

  Recruiting at 3 sites Phase 2 Baptist Health South Florida · Miami, Florida and 2 other locations · NCT06263543

• Combining pembrolizumab with cryoablation for metastatic breast cancer

  This study is testing if combining a drug called pembrolizumab with a freezing treatment can help people with advanced triple negative breast cancer feel better compared to just using the drug alone.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06246968

• Treatment with TQB2930 for advanced breast cancer

  This study is testing a new treatment called TQB2930 for people with advanced breast cancer to see if it is safe and effective, both on its own and when combined with other chemotherapy drugs.

  Recruiting at 2 sites Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chongqing, Chongqing Municipality and 1 other locations · NCT06202261

• Radiation treatment for high-risk spine cancer patients

  This study is testing a new type of radiation treatment for patients with cancer that has spread to the spine to see if it can help manage their condition without needing major surgery.

  Recruiting Phase 2 Stony Brook University · Stony Brook, New York · NCT06165419

• Treatment for Oligometastatic Breast Cancer

  This study is testing whether adding a special type of radiation therapy to standard treatment can help women with a few metastatic breast cancer spots live longer and feel better.

  Recruiting National Cancer Institute, Egypt · Cairo · NCT06144346

• Treatment for Oligometastatic Breast Cancer

  This study is testing if adding a special treatment for metastatic breast cancer, like surgery or targeted radiation, can help patients do better after starting their regular cancer therapy.

  Recruiting Phase 3 Tokyo Medical and Dental University · Bunkyō-Ku, Tokyo · NCT06135714

• BGB-43395 treatment for advanced breast cancer and other solid tumors

  This study is testing a new treatment called BGB-43395 for people with advanced breast cancer and other solid tumors to see if it works better alone or with other medications.

  Recruiting at 57 sites Phase 1 BeOne Medicines · Denver, Colorado and 60 other locations · NCT06120283

• Low dose capecitabine for older patients with advanced breast cancer

  This study is testing if a lower dose of capecitabine can help older patients with advanced breast cancer feel better after their previous treatments.

  Recruiting Phase 2 University of Alabama at Birmingham · Birmingham, Alabama · NCT06105684

• Testing enzalutamide alone or with mifepristone for advanced breast cancer

  This study is testing if the drug enzalutamide, either by itself or with mifepristone, can help people with advanced breast cancer do better than the usual chemotherapy treatments.

  Recruiting at 12 sites Phase 2 Memorial Sloan Kettering Cancer Center · Birmingham, Alabama and 11 other locations · NCT06099769

• Evaluating SKB264 for advanced breast cancer

  This study is testing a new drug called SKB264 to see if it can help people with advanced breast cancer that hasn't responded to other treatments.

  Recruiting Phase 3 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06081959

• Evaluating Bria-IMT with Checkpoint Inhibitor for Advanced Metastatic Breast Cancer

  This study is testing if a new treatment combining Bria-IMT with a checkpoint inhibitor can help people with advanced metastatic breast cancer live longer compared to other treatments their doctors might choose.

  Recruiting at 79 sites Phase 3 BriaCell Therapeutics Corporation · Phoenix, Arizona and 78 other locations · NCT06072612

• Testing FWD1802 for ER+/HER2- breast cancer

  This study is testing a new treatment called FWD1802, alone and with another drug, to see if it can help people with advanced ER+/HER2- breast cancer feel better and improve their outcomes.

  Recruiting at 20 sites Phase 1/2 Forward Pharmaceuticals Co., Ltd. · Hefei, Anhui and 21 other locations · NCT06064812

• Elacestrant with or without a CDK4/6 inhibitor for ER+/HER2- advanced or metastatic breast cancer

  This study will test whether adding a CDK4/6 inhibitor to elacestrant helps people with ER-positive, HER2-negative advanced or metastatic breast cancer who have an ESR1 mutation and prior CDK4/6 exposure.

  Recruiting at 2 sites Phase 2 Northwestern University · Chicago, Illinois and 2 other locations · NCT06062498

• Optimizing CDK 4/6-inhibitor doses for older breast cancer patients

  This study is testing if personalizing the dose of a breast cancer medication for older patients can help them get better results than just lowering the dose based on standard practices.

  Recruiting at 2 sites Phase 3 Region Örebro County · Helsinki and 11 other locations · NCT06044623

• Biomarker-driven treatment selection for metastatic breast cancer

  This study is testing if measuring a specific blood marker can help doctors decide when to change treatments for patients with certain types of advanced breast cancer to improve their chances of staying cancer-free longer.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT05977036

• Registry for patients with metastatic lobular breast cancer

  This study is collecting information from patients with metastatic lobular breast cancer to see how they respond to treatments and understand their overall health over time.

  Recruiting at 4 sites University of California, San Francisco · San Diego, California and 3 other locations · NCT05964504

• Observational study on HER2-low breast cancer treatment with Trastuzumab Deruxtecan

  This study is testing how well Trastuzumab deruxtecan works for adults with advanced HER2-low breast cancer who have already had chemotherapy.

  Recruiting at 26 sites Daiichi Sankyo · Graz and 215 other locations · NCT05945732

• Evaluating the effects of radiotherapy on patients with oligometastatic cancer

  This study is testing how well Stereotactic Ablative Radiotherapy (SABR) works for people with oligometastatic cancer to see if it can help them live longer and feel better.

  Recruiting Institut Investigacio Sanitaria Pere Virgili · Albacete, Albacete and 20 other locations · NCT05933876

• Observing outcomes of high-precision radiotherapy in metastatic breast cancer

  This study looks at how well high-precision radiation treatments work for people with metastatic breast cancer who have already had or are about to receive advanced radiation therapies.

  Recruiting Samsung Medical Center · Seoul · NCT05907681

• Combination of estradiol and olaparib for advanced breast cancer treatment

  This study is testing a new treatment combining estradiol and olaparib to see if it helps post-menopausal women with advanced breast cancer that hasn't responded to other therapies.

  Recruiting Phase 1 Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT05900895

• Evaluating Inavolisib with Phesgo for Advanced Breast Cancer

  This study is testing if a new combination of inavolisib and Phesgo can help people with advanced breast cancer caused by specific genetic changes feel better after their initial treatment.

  Recruiting at 79 sites Phase 3 Hoffmann-La Roche · Gilbert, Arizona and 191 other locations · NCT05894239

• Platform program for evaluating treatments in metastatic HER2-positive breast cancer

  This study is testing different new treatments for people with advanced HER2-positive breast cancer to see which ones work best before moving them to larger trials.

  Recruiting at 5 sites Phase 1/2 QuantumLeap Healthcare Collaborative · Birmingham, Alabama and 9 other locations · NCT05868226

• Chemotherapy with or without Tocilizumab for certain types of breast cancer

  This study is testing if adding a drug called tocilizumab to standard chemotherapy helps people with certain types of advanced breast cancer feel better compared to just chemotherapy alone.

  Recruiting at 7 sites Phase 2 Indiana University · Atlanta, Georgia and 6 other locations · NCT05846789

• Comparing two treatment combinations for hormone receptor positive metastatic breast cancer

  This study is testing two different treatment combinations to see which one works better for women with hormone receptor positive metastatic breast cancer that hasn't responded to previous treatments.

  Recruiting at 2 sites Phase 2 Korea University Guro Hospital · Seoul and 1 other locations · NCT05816655

• Blood test to monitor treatment in metastatic breast cancer

  This study is testing a new blood test to see if it can help women with metastatic breast cancer know sooner if their treatment is working.

  Recruiting at 2 sites Queen's University · Kingston, Ontario and 1 other locations · NCT05804578

• Impact of Exercise and Statins on Cancer Treatment

  This study is testing if doing supervised exercise while taking cancer drugs helps people with metastatic breast, kidney, ovarian, and prostate cancer feel better and respond better to their treatment compared to exercising on their own, and if adding a cholesterol-lowering medication can make it even more effective.

  Recruiting Phase 3 Tampere University Hospital · Tampere, Länsi-Suomi · NCT05796973

• Using SHR-A1811 for HER2-positive advanced breast cancer with brain metastases

  This study is testing a new treatment called SHR-A1811 for women with advanced HER2-positive breast cancer that has spread to the brain to see if it helps them better than current options.

  Recruiting Phase 2 Henan Cancer Hospital · Zhengzhou, Henan · NCT05769010

• Monitoring insulin levels and treating high insulin and blood sugar in breast cancer patients using pioglitazone.

  This study is testing if using pioglitazone to manage insulin and blood sugar levels can help women with metastatic breast cancer who are being treated with Alpelisib.

  Recruiting Early Phase 1 Rambam Health Care Campus · Haifa · NCT05753657

• Using Nicotinamide Riboside to Prevent Heart Problems in Breast Cancer Patients

  This study is trying to see if a supplement called nicotinamide riboside can help prevent heart problems in women with metastatic breast cancer who are receiving certain chemotherapy treatments.

  Recruiting Phase 2 University Hospital, Akershus · Lørenskog, Akershus · NCT05732051

• Combination therapy for premenopausal women with advanced ER positive breast cancer

  This study is testing different combinations of medications to see if they can help premenopausal women with advanced breast cancer that hasn't improved with previous treatments.

  Recruiting Phase 2 National Taiwan University Hospital · Taipei · NCT05720260

• Estradiol treatment for advanced breast cancer with specific mutations

  This study is testing if a hormone treatment called estradiol can help post-menopausal women with advanced breast cancer that has specific mutations feel better and live longer compared to those without those mutations.

  Recruiting Phase 2 Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT05716516

• Comparing lasofoxifene with fulvestrant for advanced breast cancer treatment

  This study is testing whether a new pill called lasofoxifene works better than fulvestrant for people with advanced breast cancer that has an ESR1 mutation.

  Recruiting at 204 sites Phase 3 LeonaBio · Scottsdale, Arizona and 223 other locations · NCT05696626

• Evaluating chemotherapy versus endocrine therapy for hormone receptor-positive metastatic breast cancer

  This study is testing whether a chemotherapy drug called capecitabine works better than hormone therapy for people with hormone receptor-positive metastatic breast cancer who have already tried other treatments.

  Recruiting at 4 sites Phase 2 Vanderbilt-Ingram Cancer Center · Birmingham, Alabama and 3 other locations · NCT05693766

• Combining alpelisib with chemotherapy for HER2 negative metaplastic breast cancer

  This study is testing whether combining a new drug called alpelisib with chemotherapy can help people with a rare and tough type of breast cancer feel better and improve their treatment results.

  Recruiting at 3 sites Phase 2 The Methodist Hospital Research Institute · Bethesda, Maryland and 2 other locations · NCT05660083

• Genomics-guided precision medicine for metastatic breast cancer

  This study is testing whether using genetic information from tumors and blood samples can help doctors create personalized treatment plans for people with metastatic breast cancer.

  Recruiting at 12 sites German Cancer Research Center · Augsburg and 11 other locations · NCT05652569

• Evaluating Vosilasarm for Advanced Breast Cancer Treatment

  This study is testing a new drug called Vosilasarm to see how well it works on its own and with other treatments for people with advanced breast cancer.

  Recruiting at 13 sites Phase 1/2 Ellipses Pharma · New Haven, Connecticut and 13 other locations · NCT05573126

• Immunotherapy for advanced metastatic solid tumors

  This study is testing a new immunotherapy called SYNC-T to see if it can help people with advanced solid tumors that haven't responded to other treatments.

  Recruiting Phase 1 Williams Cancer Foundation · Mexico City · NCT05544240

• Adding targeted radiation therapy to drug treatment for breast cancer

  This study is testing whether adding targeted radiation therapy to regular drug treatment can help people with a specific type of breast cancer keep their disease from getting worse or spreading.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT05534438

• Combination therapy for hormone receptor-positive metastatic breast cancer

  This study is testing a new combination of three medications to see if it can help people who have just been diagnosed with advanced hormone receptor-positive breast cancer or those who have had a relapse after being cancer-free for over a year.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT05524584

• Combination treatment for advanced breast cancer with specific genetic alterations

  This study is testing a new combination of three drugs to see if it can help people with advanced breast cancer that has certain genetic changes while keeping track of any side effects like high blood sugar.

  Recruiting at 10 sites Phase 1/2 SynDevRx, Inc. · Loma Linda, California and 9 other locations · NCT05455619

• Evaluating a prognostic tool for metastatic breast cancer care

  This study is trying to see if a new tool that helps doctors predict outcomes for patients with metastatic breast cancer is easy to use and helpful for improving care.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT05440929

• Digital health coaching for cancer survivors

  This study is testing whether a digital health coaching program can help cancer survivors feel better and improve their health after finishing treatment.

  Recruiting at 2 sites Pack Health · Gainesville, Florida and 6 other locations · NCT05349227

• Combining radiotherapy and systemic therapy for newly diagnosed metastatic breast cancer

  This study is testing whether combining local radiation treatment with other therapies can help people with newly diagnosed metastatic breast cancer live longer, especially those with cancer that has spread only to the bones.

  Recruiting Ankara Oncology Research and Training Hospital · Ankara · NCT05334459

• Testing a new drug for advanced solid tumors and breast cancer with specific mutations

  This study is testing a new drug called RLY-2608 to see if it can help people with advanced solid tumors and breast cancer that have specific mutations.

  Recruiting at 36 sites Phase 1 Relay Therapeutics, Inc. · Tucson, Arizona and 36 other locations · NCT05216432

• Combination of immunotherapy and chemotherapy for HER2-negative breast cancer

  This study is testing if combining two immunotherapy drugs with standard chemotherapy can help people with advanced HER2-negative breast cancer feel better and live longer.

  Recruiting at 5 sites Phase 1 University of Texas Southwestern Medical Center · Chicago, Illinois and 6 other locations · NCT05029999

• Palliative radiation combined with pembrolizumab for advanced breast cancer

  This study is testing whether combining a type of radiation therapy with a cancer-fighting drug can help women with advanced breast cancer who haven’t responded to previous treatments.

  Recruiting Phase 2 University of Louisville · Louisville, Kentucky · NCT04990921

• Using scalp cooling to prevent hair loss in metastatic breast cancer patients

  This study is testing if using a scalp cooling system during chemotherapy can help prevent hair loss in people with metastatic breast cancer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT04986579

• Patritumab deruxtecan for unresectable or metastatic hormone-receptor–positive, HER2-negative breast cancer

  This trial will try patritumab deruxtecan (U3-1402) every three weeks in adults with HER2-negative, hormone-receptor–positive advanced or metastatic breast cancer whose disease progressed after endocrine therapy plus CDK4/6 inhibitors.

  Recruiting at 10 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Dijon and 10 other locations · NCT04965766

• Evaluating BTX-A51 for advanced solid tumors and breast cancer

  This study is testing a new treatment called BTX-A51 for people with advanced solid tumors and metastatic breast cancer to see how safe it is and if it works better alone or with another medication.

  Recruiting at 4 sites Phase 1 Edgewood Oncology Inc. · Lake Mary, Florida and 5 other locations · NCT04872166

• Combining radiation therapy with pembrolizumab and olaparib for certain breast cancers

  This study tests if adding pembrolizumab, with or without olaparib, to standard radiation therapy can help women with advanced breast cancer feel better compared to just radiation therapy alone.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT04683679

• Identifying resistance to CDK4/6 inhibitors in breast cancer

  This study is trying to find out why some women with a specific type of advanced breast cancer don't respond to a common treatment that includes a CDK4/6 inhibitor and an aromatase inhibitor by collecting and analyzing their blood and tissue samples during treatment.

  Recruiting Fondazione Sandro Pitigliani · Prato, Tuscany · NCT04660435

• Using patient avatars to guide treatment for metastatic breast cancer

  This study is testing whether using patient avatars made from biopsy samples can help find the best treatments for people with metastatic breast cancer.

  Recruiting Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT04608357

• Comparing fulvestrant and capecitabine for maintenance therapy in metastatic breast cancer

  This study is testing whether fulvestrant or capecitabine works better as a follow-up treatment for women with hormone receptor-positive, HER2-negative metastatic breast cancer after their first chemotherapy.

  Recruiting at 12 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 12 other locations · NCT04263298

• Assessing bone strength in patients with metastatic cancer using CT scans

  This study is testing if special CT scans can help doctors better understand the risk of fractures in patients with bone cancer from breast cancer or lung cancer.

  Recruiting at 12 sites Hospices Civils de Lyon · Angers and 11 other locations · NCT04170634

• Improving immune response in triple negative breast cancer patients

  This study is testing a combination of treatments to see if they can boost the immune response in patients with metastatic triple negative breast cancer.

  Recruiting Phase 2 The Netherlands Cancer Institute · Amsterdam · NCT04159818

• Using engineered T cells to target a specific form of MUC1 in breast cancer

  This study is testing a new treatment using modified T cells to see if they can help people with advanced breast cancer by targeting a specific protein on cancer cells.

  Recruiting Phase 1 Minerva Biotechnologies Corporation · Duarte, California · NCT04020575

• Effect of Stereotactic Body Radiotherapy on Metastatic Cancer Treatment

  This study tests if combining a targeted type of radiation therapy with regular treatment can help people with metastatic cancer, like triple negative breast cancer and non-small cell lung cancer, live longer before their disease gets worse.

  Recruiting at 11 sites Phase 2 Memorial Sloan Kettering Cancer Center · San Carlos, California and 11 other locations · NCT03808337

• Analysis of molecular drivers in metastatic breast cancer

  This study is trying to understand how metastatic breast cancer changes during treatment by looking at tissue and blood samples from patients to find clues that could help predict how well treatments will work.

  Recruiting at 2 sites Lund University Hospital · Lund and 1 other locations · NCT03758976

• Pembrolizumab plus pegylated liposomal doxorubicin for endocrine‑resistant ER+ HER2‑ metastatic breast cancer

  This trial will try pembrolizumab with pegylated liposomal doxorubicin in women with endocrine‑resistant, ER‑positive, HER2‑negative metastatic breast cancer who have had at least two prior hormonal therapies.

  Recruiting Phase 1/2 Shaare Zedek Medical Center · Jerusalem · NCT03591276

• Registry for patients with advanced metastatic breast cancer in Southeast Netherlands

  This study is gathering information from patients with advanced breast cancer in Southeast Netherlands to see how different treatments are working in real life.

  Recruiting Academisch Ziekenhuis Maastricht · Maastricht · NCT03577197

• Pembrolizumab and Stereotactic Radiosurgery for Breast Cancer Brain Metastases

  This study is testing if combining an immunotherapy drug called pembrolizumab with a targeted radiation treatment can help people with metastatic breast cancer who have multiple brain tumors.

  Recruiting at 3 sites Phase 1/2 Weill Medical College of Cornell University · New York, New York and 2 other locations · NCT03449238

• Evaluating treatment combinations for advanced breast cancer

  This study is testing different combinations of treatments for people with advanced breast cancer to find out which ones work best and are safe.

  Recruiting at 39 sites Phase 1/2 Hoffmann-La Roche · Duarte, California and 54 other locations · NCT03424005

• Tracking treatment evolution in metastatic breast cancer since 2008

  This study looks at how treatment for metastatic breast cancer has changed since 2008 by gathering and analyzing patient information from 18 cancer centers in France.

  Recruiting at 20 sites Unicancer · Angers and 19 other locations · NCT03275311

• Evaluating high-dose methotrexate for breast cancer with leptomeningeal metastasis

  This study is testing if high-dose methotrexate can help breast cancer patients with leptomeningeal disease feel better and improve their treatment options.

  Recruiting at 2 sites Phase 2 Wake Forest University Health Sciences · Baltimore, Maryland and 2 other locations · NCT02422641

• Understanding genetic changes in metastatic breast cancer

  This study is trying to find out how genetic changes in metastatic breast cancer affect treatment responses by collecting samples from patients who have recently been diagnosed or relapsed.

  Recruiting at 10 sites Jules Bordet Institute · Brussels and 51 other locations · NCT02102165

NIH-funded research (newest 40 of 45)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding FGFR1-amplified breast cancer to overcome endocrine resistance

  This project explores why a type of breast cancer with FGFR1 changes stops responding to hormone therapy and looks for new combination treatments that may help patients live longer.

  NIH research Stanford University · Stanford, United States · NIH-11523882

• Oral fulvestrant as the next standard of care for ER+ metastatic breast cancer

  A new oral formulation of fulvestrant is being tested to help people with ER-positive metastatic breast cancer have a longer, better-tolerated response to treatment.

  NIH research Veramorph, LLC · Norwood, United States · NIH-11457452

• Fit2ThriveMB: A digital activity program to help people with metastatic breast cancer feel better and stay active

  A digital, at-home physical activity program designed for people with metastatic breast cancer to improve quality of life and daily functioning.

  NIH research Northwestern University · Chicago, United States · NIH-11445597

• Acupuncture to ease symptoms for people with metastatic breast cancer

  A clinical trial will test whether weekly acupuncture for 12 weeks can reduce symptom burden for people with metastatic breast cancer who are on standard therapy.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11441799

• Predicting end-of-life timing to guide better care for metastatic breast cancer

  A clinician-facing project tests a breast cancer prognostic tool in everyday oncology care to help guide conversations and timely hospice referrals for patients nearing the end of life.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11415410

• Combining antibody-drug conjugates with mechanism-based therapies to treat metastatic triple-negative breast cancer

  A research team is testing new combination strategies that pair antibody-drug conjugates with other targeted treatments to better treat metastatic triple-negative breast cancer.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11414842

• Personalized therapies for metastatic breast cancer using patient-derived models

  Doctors and researchers are testing how patient-derived tumor models can help find effective treatments for metastatic breast cancer and predict which therapies will work based on molecular clues.

  NIH research Utah State Higher Education System--University of Utah · Salt Lake City, United States · NIH-11389275

• Whole-food, plant-based eating program for metastatic breast cancer patients

  A remote 26-week plant-based eating program is being tested to improve quality of life and reduce treatment-related symptoms for women with metastatic breast cancer.

  NIH research University of Rochester · Rochester, United States · NIH-11368956

• Multi-organ breast cancer model using patient-like tissues to speed anti-metastatic drug development

  A small business grant is funding the creation of a lab model that mimics how breast cancer spreads to bone, liver, and lung so new anti-metastatic drugs can be developed faster.

  NIH research Xylyx Bio, INC. · Brooklyn, United States · NIH-11352532

• Targeted Prodrug Cytokines for Metastatic Breast Cancer Immunotherapy

  A new approach uses tumor-activated, cytokine-based therapies designed to reach metastatic breast cancer by crossing the blood-brain barrier in pre-clinical studies.

  NIH research Ohio State University · Columbus, UNITED STATES · NIH-11350465

• Targeted palliative care for people with metastatic breast cancer

  This program offers a short series of focused palliative care visits to people with metastatic breast cancer who are likely to have limited time left.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11333288

• Preventing and treating breast cancer spread to the brain and bones

  New brain‑penetrating drug versions and bone‑targeted drug conjugates for people with metastatic breast cancer that has spread to the brain or bones.

  NIH research University of Tennessee Health Sci Ctr · Memphis, United States · NIH-11312597

• Lowering HSF1 to help immune T cells enter metastatic breast tumors

  This work looks at whether lowering a protein called HSF1 can help immune T cells get into metastatic breast tumors for people with metastatic breast cancer.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-11310107

• Nanoparticle therapy to boost immune attack on metastatic breast cancer

  Nanoparticles plus blockers deliver immune-activating drugs to suppressive tumor macrophages in metastatic breast cancer to help checkpoint inhibitor treatments work better.

  NIH research University of Illinois at Urbana-Champaign · Champaign, United States · NIH-11285417

• Every Day Counts — a lifestyle program for women with metastatic breast cancer

  This program helps women living with metastatic breast cancer use exercise, strength training, and nutrition support to improve strength, body composition, blood markers, and daily quality of life.

  NIH research Medical College of Wisconsin · Milwaukee, United States · NIH-11283938

• How Osterix-positive bone-lineage cells help breast cancer grow and spread

  Seeing if Osterix-positive bone-lineage cells in the tumor environment help breast cancer grow and spread and whether targeting them could improve outcomes for people with breast cancer.

  NIH research Washington University · Saint Louis, United States · NIH-11258864

• How tumor metabolism changes immune response in metastatic triple-negative breast cancer

  This project looks at how the enzyme PFKFB4 alters tumor metabolism and the immune response in people with metastatic triple-negative breast cancer.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11248412

• Using PTPmu to find and treat breast cancer that has spread to the brain

  Researchers are developing PTPmu-targeted imaging and treatment tools to help people with breast cancer that has metastasized to the brain.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-11228392

• Energize-MBC: a web-based fatigue program for women with metastatic breast cancer

  This project will adapt a cognitive behavioral therapy program delivered online to help women with metastatic breast cancer who have tiring side effects from CDK4/6 inhibitor treatment.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11194344

• How breast cancer spreads and how surrounding tissues change its behavior

  This project studies how breast cancer cells evolve as they spread and how nearby tissues affect their response to treatments for people with metastatic breast cancer.

  NIH research Stanford University · Stanford, United States · NIH-11178532

• Better treatments for metastatic breast cancer using patient-derived tumor models

  Researchers use lab-grown tumor models made from people with metastatic breast cancer to find drug combinations and molecular markers that could help pick better treatments.

  NIH research Utah State Higher Education System--University of Utah · Salt Lake City, United States · NIH-11177952

• Turning bone tumor-supporting immune cells into cancer-fighting cells for breast cancer that has spread to bone

  This work aims to change immune cells that help tumors in bone into cells that fight cancer for people with breast cancer that has spread to bone.

  NIH research Veterans Health Administration · Nashville, United States · NIH-11131023

• A platform to test breast cancer treatments using patient-derived organ models.

  This study is working on a new way to understand how breast cancer spreads to other parts of the body, using tiny models made from real patient tissues, to help find better treatments that are tailored just for you.

  NIH research Xylyx Bio, INC. · Brooklyn, United States · NIH-11109706

• Improving end-of-life care for patients with metastatic breast cancer

  This study is looking to improve the care and support for people with metastatic breast cancer by helping them and their doctors talk better about their wishes and needs as they near the end of life, so they can get the best care possible.

  NIH research Massachusetts General Hospital · Boston, United States · NIH-11103432

• Investigating if some patients with HER2+ metastatic breast cancer can be cured

  This study is looking at how some patients with HER2+ metastatic breast cancer might be able to achieve a cure using new targeted treatments, and it will track tiny amounts of cancer DNA in their blood to see if they can safely stop treatment when there’s no sign of disease.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11060038

• Improving treatment for brain and bone metastases in breast cancer

  This study is looking for ways to help people with metastatic breast cancer by creating new treatments that can better reach and fight cancer in the brain and bones, which could lead to improved survival and slower disease progression.

  NIH research University of Tennessee Health Sci Ctr · Memphis, United States · NIH-11059072

• Understanding how metabolic changes affect the immune response in metastatic breast cancer

  This study is looking at how certain cancer cells in triple-negative breast cancer adapt to survive and avoid being attacked by the immune system, focusing on a specific enzyme called PFKFB4, to find new ways to boost treatment and help patients fight their cancer better.

  NIH research Roswell Park Cancer Institute Corp · Buffalo, United States · NIH-11058584

• Using targeted nanocarriers to improve treatment for metastatic breast cancer

  This study is testing a new way to treat metastatic breast cancer by using tiny carriers to deliver special drugs right to the immune cells in tumors, hoping to help more patients, especially those with triple-negative breast cancer, respond better to existing treatments.

  NIH research University of Illinois at Urbana-Champaign · Champaign, United States · NIH-11052550

• Increasing immune cells in metastatic breast cancer by targeting HSF1.

  This study is looking at how blocking a protein called HSF1 might help boost the number of immune cells, especially CD8+ T cells, in breast cancer tumors that have spread, with the goal of finding better ways to improve cancer treatments for patients.

  NIH research Indiana University Indianapolis · Indianapolis, United States · NIH-11049520

• Investigating how specific bone cells influence breast cancer growth and spread

  This study is looking at special bone cells in breast cancer to see how they might help tumors grow and spread, and it aims to find new ways to treat the disease by understanding how these cells interact with cancer.

  NIH research Washington University · Saint Louis, United States · NIH-11026446

• A lifestyle program for women with metastatic breast cancer

  This study is creating a friendly program for women with metastatic breast cancer to help them feel better by encouraging exercise and healthy habits, aiming to improve their overall well-being and manage symptoms related to their treatment.

  NIH research Medical College of Wisconsin · Milwaukee, United States · NIH-11017029

• Combining antibody-linked cancer medicines for metastatic triple-negative breast cancer

  This project tests whether pairing antibody-linked cancer drugs with other targeted treatments can help people with metastatic triple-negative breast cancer get better responses with fewer side effects.

  NIH research Dana-Farber Cancer Inst · Boston, United States · NIH-11015466

• Improving early palliative care for Black women with metastatic breast cancer

  This study is testing a new support program designed for Black women with metastatic breast cancer, where community members help provide care and understanding for the unique challenges they face.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-10988297

• Identifying and targeting metastatic breast cancer using a specific biomarker

  This study is looking at how breast cancer cells spread along nerves and is testing a special protein that could help doctors find these tumors more easily and improve treatment options for patients, especially if the cancer has spread to the brain.

  NIH research Case Western Reserve University · Cleveland, United States · NIH-10978207

• Understanding how breast cancer spreads and resists treatment

  This study is looking at how breast cancer spreads and why some treatments don't work, using special lab models and samples from patients to find new ways to improve care for those with breast cancer.

  NIH research Stanford University · Stanford, United States · NIH-10977547

• How couples talk about sexuality when facing metastatic breast cancer

  This study looks at how couples talk about sex and closeness when one partner has metastatic breast cancer, hoping to find ways to improve their relationship and support each other during this tough time.

  NIH research University of Connecticut Storrs · Storrs-Mansfield, United States · NIH-10953854

• Improving end-of-life care for patients with metastatic breast cancer

  This study is working to improve care for patients with advanced breast cancer by creating a helpful tool that predicts when someone might be nearing the end of life, so doctors can have important conversations about care options and hospice support.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-10917265

• Understanding how breast cancer spreads and resists treatment

  This study is looking into how breast cancer spreads and why some treatments don't work, using special lab models made from patient samples to find new ways to improve treatment for people with breast cancer.

  NIH research Stanford University · Stanford, United States · NIH-10905002

• Understanding and treating genetic changes in metastatic breast cancer

  This study is looking at how certain genetic changes in metastatic breast cancer, especially those caused by the APOBEC enzyme, might make the cancer harder to treat, and it’s for patients who want to learn more about their cancer and how to get the best treatment.

  NIH research Sloan-Kettering Inst Can Research · New York, United States · NIH-10902114

• Targeting a specific enzyme to treat breast cancer that has spread to the brain

  This study is looking at how a common enzyme in breast cancer that spreads to the brain can be targeted using everyday heartburn medications to make cancer treatments work better for patients.

  NIH research University of Toledo Health Sci Campus · Toledo, United States · NIH-10884918

Related topics

Quick answers

How many Metastatic Breast Cancer clinical trials are recruiting right now?

140, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 52 countries. The most sites are in United States (71 trials), China (26 trials), France (20 trials), Spain (19 trials), Australia (14 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 38, Phase 1: 19, Phase 3: 17, Phase 1/2: 14. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →